Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00847054 · ClinicalTrials.gov registry record · Phase 1
A Study of of MORAb-004 in Subjects With Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Morphotek.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 3
- Study locations
NCT00847054: Completed Phase 1 study of Solid Tumor, sponsored by Morphotek.
NCT00847054 is a Phase 1 study of Solid Tumor that has completed, run by Morphotek. The registered enrollment target is 80 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (64% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00847054, a Phase 1 study of Solid Tumor, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety of multiple intravenous infusions of MORAb-004.
Primary Outcome
Safety is evaluated by clinical assessment, monitoring of adverse events, laboratory evaluations, ECG.
Conditions Studied
Interventions
- DRUG MORAb-004 (monoclonal antibody to TEM1)
Study Locations (3)
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2009-03 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
What the finished NCT00847054 record still lists
NCT00847054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which MORAb-004 (monoclonal antibody to TEM1) is the first listed.
NCT00847054 reports a single indexed study location in Maryland, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00847054 about?
NCT00847054 is a clinical study titled "A Study of of MORAb-004 in Subjects With Solid Tumors". The purpose of this study is to determine the safety of multiple intravenous infusions of MORAb-004.
What is the current status of trial NCT00847054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2009-03. Estimated completion is 2014-04.
What conditions does trial NCT00847054 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT00847054?
The interventions under investigation include: MORAb-004 (monoclonal antibody to TEM1) (DRUG).
Who is sponsoring clinical trial NCT00847054?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00847054 being conducted?
This trial has 3 study locations across Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00847054's enrollment target sits among peer trials
80 98th of 196 higher than 98 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia